Please login to the form below

Not currently logged in

Look to the future

PwC pharma survey predicts a move from marketing to more R&D

missing image fileThe pharma industry's business model is "economically unsustainable" and more money needs to be moved from marketing to R&D, according to a new report on the future of the industry by PricewaterhouseCoopers (PwC).

The study, Pharma 2020: The Vision - Which Path Will You Take? says pharma companies' reliance on heavy marketing of a few drugs in order to generate huge sales meant that "the current pharmaceutical industry business model is both economically unsustainable and operationally incapable of acting quickly enough to produce the types of innovative treatments demanded by global markets".

Dr Steve Arlington, global pharmaceutical R&D advisory leader at PwC, and principal author of the report, commented: "The pharma industry will not be in a strong position to capitalise on opportunities unless R&D productivity improves. The core challenge for the industry is a lack of innovation. The industry is investing twice as much in R&D as it was a decade ago to produce two-fifths of the new medicines it then produced. It is simply an unsustainable business model."

According to Arlington, over the next decade, the industry must shift investment focus toward research and away from sales and marketing.

"Pharma's traditional strategy of placing big bets on a few small molecules, marketing them heavily into primary care with the aspiration of achieving blockbuster sales, will no longer suffice," he said.

"It must focus on the development of medicines that prevent, treat or cure. These must demonstrate tangible benefits and tackle unmet medical needs. Governments and payers must play their part and ensure the industry is rewarded for these efforts."

One of his suggestions was that patent protection for drugs could be extended.

The report's authors believe that by 2020 the supply chain will expand to accommodate a wider range of medicines and markets, which will mean the sales and marketing process will become more concentrated. As a result pharma companies will focus most of their efforts on the policy-makers and payers who increasingly determine which medicines are prescribed.

"By 2020, a single pan-European agency could replace national bodies such as UK's National Institute for Health and Clinical Excellence (NICE)," the report states.

Patients will play an increasing role in the sales and marketing equation, according to the report, as they pay more and more of their healthcare bills.

Pricing of drugs will also change dramatically. The industry will almost certainly be expected to price therapies that have live licenses conditional on further in-life testing on a sliding scale, with price rises tied to the extension of the license and quota of patients for whom a treatment can be prescribed, says the report.

The pharmaceuticals market is set to grow and is expected to more than double in value to USD 1.3tn by 2020. The increase is driven by soaring worldwide demand for drugs and preventative treatments. This is partly a result of increasing prosperity but also because of the rise in obesity and the ageing population.

missing image file

...Communications firm Eurocom Healthcare Communications has launched its agency network, Eurocom Healthcare Communications Network. The network has member agencies in France, Germany, Italy and Spain, the UK and US. The network will develop and deliver healthcare communications packages for pharma and consumer healthcare firms targeting the European market. It will offer a broad range of services including advertising, med ed and PR. The network has already been involved with the co-marketed global launch of the Parkinson's disease drug Azilect for Teva and Lundbeck, and is currently working on an international consumer healthcare launch.

19th June 2007


COVID-19 Updates and Daily News

Featured jobs


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...